Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 31, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

August 16, 2022

On Tuesday, 37 stocks hit new 52-week lows.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 12, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

FDA Pushes Decision Date For Reata's Genetic Neuromuscular Disease Candidate ↗

August 09, 2022

Via Benzinga

Recap: Reata Pharmaceuticals Q2 Earnings ↗

August 08, 2022

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q2 earnings results on Monday, August 8, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 09, 2022

Via Benzinga

Baird Maintains Neutral Rating for Reata Pharmaceuticals: Here's What You Need To Know ↗

August 09, 2022

Baird has decided to maintain its Neutral rating of Reata Pharmaceuticals (NASDAQ:RETA) and lower its price target from $37.00 to $27.00. Shares of Reata Pharmaceuticals are trading down 8.1% over...

Via Benzinga

Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia

August 09, 2022

From Reata Pharmaceuticals, Inc.

Via Business Wire

Nasdaq Turns Lower; Crude Oil Rises Over 1% ↗

August 08, 2022

U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday.

Via Benzinga

Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday ↗

August 09, 2022

Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 08, 2022

Via Benzinga

Dow, Nasdaq Enjoy Triple-Digit Gains Midday ↗

August 08, 2022

Stocks are extending this morning's gains.

Via Talk Markets

Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

August 08, 2022

Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6...

Via Benzinga

Dow Jumps Over 150 Points; Karuna Therapeutics Shares Spike Higher ↗

August 08, 2022

U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.

Via Benzinga

Why Reata Pharma Shares Are Trading Lower After Q2 Earnings Update? ↗

August 08, 2022

Reata Pharmaceuticals Inc (NASDAQ: RETA) completed a mid-cycle communication meeting with the FDA regarding the marketing application review status for omaveloxolone for Friedreich's ataxia.

Via Benzinga

Why U.S. Stocks Are Trading Higher; Tyson Foods Earnings Miss Views ↗

August 08, 2022

U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 08, 2022

Via Benzinga

Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

August 08, 2022

From Reata Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For August 8, 2022 ↗

August 08, 2022

Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.

Via Benzinga

Reata Pharmaceuticals Earnings Preview ↗

August 05, 2022

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Reata...

Via Benzinga

Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022

August 01, 2022

From Reata Pharmaceuticals, Inc.

Via Business Wire

Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors

July 11, 2022

From Reata Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 07, 2022

Gainers

Via Benzinga

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday ↗

July 06, 2022

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.

Via Benzinga

Reata Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

June 09, 2022

According to data from Benzinga Pro, during Q1, Reata Pharmaceuticals's (NASDAQ:RETA) reported sales totaled $914.00 thousand. Despite a 13.52% increase in earnings, the company posted a loss of $73.84...

Via Benzinga

Where Reata Pharmaceuticals Stands With Analysts ↗

May 27, 2022

Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review ↗

May 26, 2022

Reata Pharmaceuticals (NASDAQ: RETA) announced that the U.S. Food and Drug Administration has accepted New Drug Application (NDA) for its lead drug candidate omaveloxolone for the treatment of patients...

Via Benzinga

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review ↗

May 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia

May 26, 2022

From Reata Pharmaceuticals, Inc.

Via Business Wire

NASDAQ:RETA Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Reata Pharmaceuticals, Inc. ↗

May 10, 2022

San Diego, CA -- (SBWIRE) -- 05/10/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Reata Pharmaceuticals, Inc.

Via SBWire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.